Presentation is loading. Please wait.

Presentation is loading. Please wait.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Published byShawn Boyd Modified over 5 years ago

Similar presentations

Presentation on theme: "Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem."— Presentation transcript:

1 Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem Cell Transplantation  Bipin N. Savani, Stephan Mielke, Katayoun Rezvani, Aldemar Montero, Agnes S. Yong, Laura Wish, Jeannine Superata, Roger Kurlander, Anurag Singh, Richard Childs, A. John Barrett  Biology of Blood and Marrow Transplantation  Volume 13, Issue 10, Pages (October 2007) DOI: /j.bbmt Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 A, LC30 distribution in AML, ALL, and CML; B, comparison LC30, day 60 lymphocyte (LC60), and day 90 lymphocyte (LC90) counts posttransplantation between group with LC30 <450/μL and >450/μL. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Time to A, neutrophil, and B, platelet engraftment in patients with LC30 <450/μL versus >450/μL. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Cumulative incidence of A, aGVHD, and B, cGVHD and incidence in patients with LC30 above and below 450/μL. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 A, Cumulative incidence of nonrelapse mortality; B, LC30, disease risk (HR, high risk; SR, standard risk), and NRM. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 A, Cumulative incidence of relapse; B, LC30, disease risk (HR, high risk; SR, standard risk), and relapse; C, LC30 and relapse in acute lymphoblastic leukemia (ALL). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 A, Overall survival; B, LC30, disease risk (HR, high risk; SR, standard risk), and survival; C, LC30 and survival in acute lymphoblastic leukemia (ALL). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem."

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.
Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination  Bipin.

Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination  Bipin.
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies  Katarina Le.

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies  Katarina Le.
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia  Daisuke Tomizawa, Shiro Tanaka, Tadakazu.

Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia  Daisuke Tomizawa, Shiro Tanaka, Tadakazu.
Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.

Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 
Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.
Betty T. Tran, Abigail Halperin, Jason W. Chien 

Betty T. Tran, Abigail Halperin, Jason W. Chien 
Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Similar presentations

Ads by Google